论文部分内容阅读
目的评价Ag85a-卡介苗重组疫苗对结核病预防及治疗效果,期望得到对结核病的预防效果强于卡介苗的重组疫苗。方法观察Ag85a-卡介苗重组疫苗对结核分支杆菌感染的预防试验和治疗实验中实验动物半数死亡时间、一定时间内的死亡率、大体病变、T细胞及B细胞免疫功能等指标评价各卡介苗重组疫苗的抗结核作用。结果用Ag85a-卡介苗重组疫苗对结核分支杆菌感染进行预防,Ag85a-卡介苗重组疫苗及卡介苗与生理盐水对照组比都能延长结核分枝杆菌感染小鼠的半数死亡时间,降低2个月内的死亡率。结核分枝杆菌攻击后2个月,处死小鼠时,Ag85a-卡介苗重组疫苗免疫组小鼠脏器与其他各组之间无显著差别。各组小鼠脏器研磨、消化后稀释为不同梯度进行培养Ag85a-卡介苗重组疫苗免疫小鼠肺脏结核分支杆菌生长的最低稀释度主要集中在10-5,肝、脾结核分枝杆菌生长的最低稀释度主要集中在10-4。抗体检测结果及淋巴细胞增殖实验各组间无显著差别。卡介苗重组疫苗对结核病的治疗试验结果中半数死亡时间与2个月内的死亡率反而不如预防的效果,说明卡介苗或卡介苗重组疫苗等活体疫苗作为结核病治疗性疫苗无明显的治疗效果。结论初步实验表明:Ag85a-卡介苗重组疫苗对结核分支杆菌感染的预防作用与卡介苗无显著区别,卡介苗或Ag85a-卡介苗重组疫苗等活体疫苗作为结核病治疗性疫苗无明显的治疗效果。
Objective To evaluate the efficacy of recombinant Ag85a-BCG vaccine in the prevention and treatment of tuberculosis, expecting to get a better vaccine against tuberculosis than BCG vaccine. Methods To observe the preventive and curative effects of recombinant Ag85a-BCG vaccine against Mycobacterium tuberculosis infection and the half dead time of experimental animals, mortality, general pathological changes, immune function of T cells and B cells in the treatment experiment Anti-TB effect. Results Ag85a-BCG recombinant vaccine was used to prevent Mycobacterium tuberculosis infection. The Ag85a-BCG recombinant vaccine and BCG-B can prolong the half-life of Mycobacterium tuberculosis infected mice and reduce the death within 2 months rate. Two months after the challenge with Mycobacterium tuberculosis, mice were sacrificed, Ag85a-BCG vaccination group mice immune organs and no significant difference between the other groups. Mice in each group were grinded and digested and diluted to different gradients for culture. The minimal dilutions of Mycobacterium tuberculosis in the lungs of mice immunized with Ag85a-BCG vaccine were mainly concentrated in 10-5, the lowest in Mycobacterium tuberculosis Dilution is mainly concentrated in 10-4. Antibody test results and lymphocyte proliferation test no significant difference between the various groups. BCG vaccine recombinant vaccine for tuberculosis treatment test results in half the time and mortality within 2 months instead of the effect of prevention, indicating that BCG or BCG recombinant vaccine and other live vaccines as tuberculosis therapeutic vaccine no significant effect. Conclusion Preliminary experiments showed that the preventive effect of recombinant Ag85a-BCG vaccine against Mycobacterium tuberculosis infection was not significantly different from that of BCG vaccine. The live vaccine such as BCG vaccine or recombinant Ag85a-BCG vaccine had no significant therapeutic effect as a therapeutic vaccine against tuberculosis.